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CAF hierarchy driven by pancreatic cancer cell
p53-status creates a pro-metastatic and
chemoresistant environment via perlecan
Claire Vennin et al.#
Heterogeneous subtypes of cancer-associated fibroblasts (CAFs) coexist within pancreatic
cancer tissues and can both promote and restrain disease progression. Here, we interrogate
how cancer cells harboring distinct alterations in p53 manipulate CAFs. We reveal the
existence of a p53-driven hierarchy, where cancer cells with a gain-of-function (GOF) mutant
p53 educate a dominant population of CAFs that establish a pro-metastatic environment for
GOF and null p53 cancer cells alike. We also demonstrate that CAFs educated by null p53
cancer cells may be reprogrammed by either GOF mutant p53 cells or their CAFs. We
identify perlecan as a key component of this pro-metastatic environment. Using intravital
imaging, we observe that these dominant CAFs delay cancer cell response to chemotherapy.
Lastly, we reveal that depleting perlecan in the stroma combined with chemotherapy prolongs
mouse survival, supporting it as a potential target for anti-stromal therapies in pancreatic
cancer.
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Pancreatic cancer (PC) is one of the largest causes of cancer-related death, with ~7% survival rate at 5 years post-diagnosis1. New therapeutics have been employed to
improve patient outcomes; however, median survival remains less
than 1 year2,3. Consequently, identifying new therapeutic targets
is a critical need in this disease.
TP53 is one of the most commonly altered genes in human
cancer and changes in this gene correlate with poor patient
outcomes in a broad range of tumor types including PC4–9. Wild-
type (WT) TP53 is a tumor-suppressor, which acts as the guar-
dian of the genome to trigger DNA repair or elimination of
damaged cells10–12. Mutations in TP53 most commonly induce
either a loss of WT function (null mutations) or acquisition of
pro-tumorigenic functions (gain-of-function (GOF) mutations).
Similarly, loss of p53 expression may also occur as a result of
genetic aberrations4.
Genetically engineered mouse models (GEMMs) of PC have
provided key insights into how alterations in TP53 drive disease
progression13–15. We and others have used the poorly-metastatic
Pdx1-Cre; LSL-K-rasG12D/+; LSL-p53fl/+ (KPflC) and the highly
metastatic Pdx1-Cre; LSL-K-rasG12D/+; LSL-p53R172H/+ (KPC)
mouse models. These models differ only in the p53 status of
pancreatic epithelial cells and previous work demonstrated that
mutant p53R172H in the epithelial cells drove the progression of
invasive and metastatic PC over and above the effects of loss-of-
p538,16–19, in agreement with observations in patients4.
While the role of p53 mutations in driving cancer cell behavior
has been extensively studied4, here we investigate whether altera-
tions in p53 in pancreatic tumor cells trigger cell extrinsic effects
and influence features of surrounding stromal cancer-associated
fibroblasts (CAFs). Pancreatic tumors are commonly characterized
by stromal remodeling2,20,21, which leads to altered interactions
between cancer cells and their surrounding environment. We and
others have previously demonstrated that re-shaping the pancreatic
stroma can impair tumor progression and improve the efficacy of
standard-of-care therapies2,22–27. This feedback is reciprocal, and
cancer cells with distinct characteristics have been shown to locally
tune the tumor stroma28–30. For instance CAFs, which are recruited
and activated during cancer development30,31, play a critical role in
establishing a protective and pro-tumorigenic environment2,32, and
as such represent an attractive therapeutic target. However, chronic
ablation of CAFs in pancreatic tumors has yielded distinctly mixed
results, highlighting how CAFs can both promote and impair
cancer progression28,32–36. In addition, it has become clear that not
all CAFs are alike; for example, spatially distinct populations of
CAFs were shown to play different roles in cancer progression30.
Consequently, understanding the intricate, cell-specific crosstalk
occurring between distinct cancer and stromal cell populations will
be critical to develop effective stromal-based therapeutics for PC,
which is a highly molecularly heterogeneous disease5,9,30,37,38.
In this study, we characterize CAFs isolated from KPflC (p53
null) and KPC (GOF mutant p53) end-stage primary tumors. We
probe short and long-range interactions between the cancer cells
and their CAFs in both tumor types to interrogate how CAF
reprogramming by the respective KPflC and KPC cancer cells
regulate PC progression. We unravel how cells with different
p53 status can influence one another to modulate invasion,
metastasis and response to chemotherapy. We also present evi-
dence that manipulating the stromal deposition of perlecan
(heparin sulphate proteoglycan 2, HSPG2) may offer future
therapeutic opportunities in this devastating disease.
Results
Isolation and characterization of primary CAFs. CAFs were
isolated from primary tumors developed in the poorly-metastatic
KPflC GEMM (Fig. 1a top panel) or in the highly metastatic KPC
GEMM (Fig. 1a lower panel). KPflC and KPC mice were crossed
with the LSL-E-cadherin-GFP reporter mouse, where epithelial
cancer cells express GFP at the cell-cell junction while matched
CAFs from the respective models do not39. Once autochthonous
PDAC developed fully (mice > 150 days old), CAFs were isolated by
mechanical disaggregation of the primary tumor and fluorescence
activated cell sorting (FACS, Fig. 1a and Methods section)29,40.
Following FACS isolation, imaging of GFP in cancer cells and
matched CAFs confirmed that CAFs isolated from both GEMMs
do not express E-cadherin-GFP (Fig. 1b), while immunohis-
tochemistry (IHC) and immunofluorescence analyses of markers
for CAFs29 (Fig. 1c) and pancreatic epithelial cancer cells (Fig. 1d)
validated the identity and purity of the isolated CAFs. CAF acti-
vation was confirmed using an in vitro collagen contraction assay
(Fig. 1e and Supplementary Fig. 1a)22,39. While both CAF popu-
lations were able to actively remodel collagen, there was a greater
degree of contraction in CAF matrices isolated from KPC tumor
compared to KPflC tumor (hereafter referred to as mutant-
educated CAFs, or mt-e-CAFs and as flox-educated-CAFs, or fl-e-
CAFs, respectively (Fig. 1f and Supplementary Fig. 1a)). Further,
markers of CAF contractility (pMLC, pMYPT1, and ACTA222,41)
were found to be expressed at a higher level in mt-e-CAFs com-
pared to fl-e-CAFs (Supplementary Fig. 1b). We observed that the
expression of FAP, a marker of CAF activation37,42, was higher in
mt-e-CAFs compared to fl-e-CAFs when embedded in a collagen
matrix but not when cultured in 2D (Supplementary Fig. 1b, c),
suggesting a context-specific difference in activation between the
CAF populations.
We then assessed the properties of collagen matrices remodeled
by fl-e-CAFs and by mt-e-CAFs. Using shear rheology analysis
and atomic force microscopy, we found that mt-e-CAFs form
mechanically stiffer matrices than fl-e-CAFs (Fig. 1g and
Supplementary Fig. 1d, e). Polarized imaging of picrosirius red
staining22,43 in CAF-collagen matrices demonstrated a significant
increase of fibrillar collagen density in matrices remodeled by mt-
e-CAFs compared to matrices established by fl-e-CAFs (Fig. 1h).
This was confirmed by Second Harmonic Generation (SHG)
imaging (Fig. 1i) and via analysis of collagen fiber ultrastructure
using grey-level co-occurrence matrix (GLCM) assessment (Fig. 1j
and Supplementary Fig. 1f)22,25,44. Similarly, we found higher
levels of fibrillar collagen in autochthonous primary tumors in
highly-metastatic KPC tumors compared to poorly-metastatic
KPflC tumors (Fig. 1k), demonstrating that the isolated CAFs
recapitulate critical features of the ECM found in native pancreatic
tumor tissues. The phenotype of CAFs can be altered during
in vitro culture and we performed contraction assays to compare
the properties of CAFs after FACS isolation (early) with those that
have been subjected to 10 population doublings (late). We found
that mt-e-CAFs consistently form smaller matrices with higher
fibrillar collagen content compared to fl-e-CAFs, both at early and
late passages (Supplementary Fig. 1g, h), demonstrating that the
properties of the isolated CAFs persist following in vivo education.
For further experiments, we worked with early passages of both
CAFs, to avoid the possibility of spontaneous immortalization.
fl-e-CAFs can be further educated by mt-cells. We and others
previously demonstrated that PC is a molecularly heterogeneous
disease5,9,30,37,38, where spatially distinct regions of the tumor
tissue can host different cancer cell and CAF populations that
may interact via direct, local or long-range communication within
the tumor tissue (Fig. 2a). As such, cancer cells harboring a GOF
mutant p53 (hereafter referred to as mt-CCs) could co-opt and
activate local fibroblasts, while in a spatially distinct region of the
tumor tissue, cancer cells with a loss of p53 (herein referred to as
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fl-CCs), which are less invasive, can recruit and shape different
CAF populations45–47(Fig. 2a (i)). To ask whether signaling
across the tumor tissue also exists between these subpopulations
(Fig. 2a (ii, iii)), we monitored how direct and long-range inter-
actions between cancer cells and CAFs isolated from the poorly-
metastatic and highly-metastatic GEMMs affect key events of
cancer progression.
To mimic long-range interactions between CC and CAF
populations during ECM remodeling, we treated contraction
assays of fl-e-CAFs (Fig. 2b) and mt-e-CAFs (Fig. 2c) with
conditioned media (CM) generated by fl-e-CAFs, mt-e-CAFs,
fl-CCs, or mt-CCs. fl-e-CAF matrices demonstrated an increase
in fibrillar collagen density upon treatment with CM generated by
mt-e-CAFs or by mt-CCs compared to CM generated by fl-e-
CAFs or by fl-CCs (Fig. 2b). Conversely, treating mt-e-CAF
matrices with CM generated by fl-e-CAFs, fl-CCs or mt-CCs did
not significantly alter collagen birefringence compared to
treatment with CM generated by mt-e-CAFs (Fig. 2c). This
suggests that factors secreted by mt-e-CAFs or by mt-CCs can
potentiate fl-e-CAFs to increase matrix remodeling.
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As cancer cell invasion can be regulated by the properties of the
surrounding ECM as well as by CAF-derived signaling26,48–51, we
interrogated how cancer cell invasion can be influenced by direct
and long-range interactions between the four cell subtypes22,39,43.
mt-e-CAFs create a permissive environment for invasion. fl-
CCs and mt-CCs were seeded onto matrices generated by either
fl-e-CAFs or mt-e-CAFs and allowed to invade (Fig. 2d).
p53 status in fl-CCs and mt-CCs was confirmed using IHC
staining (Supplementary Fig. 2a). In line with previous studies
in vivo16,18, fl-CCs invaded poorly into matrices remodeled by
their matched fl-e-CAFs (Fig. 2d, e), while mt-CCs were highly
invasive in matrices generated by their matched mt-e-CAFs.
Interestingly, fl-CCs were able to invade into matrices remodeled
by mt-e-CAFs to a similar degree as mt-CCs (Fig. 2d, e), while
mt-CCs invaded independently of the CAF-driven matrix
remodeling (Fig. 2d, e). Similar changes in cell invasiveness were
found using fl-CCs transfected with either a control empty vector
(EV) or with the human equivalent of murine p53R172H
(p53R175H, Supplementary Fig. 2b, c18,19,52,53). This suggests that
CAFs educated by cancer cells with a GOF mutant p53 provide
cancer cells with pro-invasive cues that are not present in fl-e-
CAF matrices. The enhanced ability of fl-CCs to invade into
matrices generated by mt-e-CAFs could potentially be due to the
increased stiffness found in these matrices (Fig. 1g and Supple-
mentary Fig. 1d, e), in line with previous work49.
To dissect how direct contact between CAFs and CCs
influences cancer cell motility, we imaged the interactions
between t-RFP labeled CAFs and GFP labeled CCs co-seeded
onto a cell-derived matrix (CDM, Supplementary Fig. 2d22,54).
We quantified coordinated cell movement, or streaming, using
image anisotropy22,55. Similarly to Fig. 2d, e, fl-CC collective
migration was enhanced in the presence of mt-e-CAFs compared
to fl-e-CAFs (Supplementary Fig. 2e). In contrast, mt-CC
streaming was not significantly different in the presence of mt-
e-CAFs versus fl-e-CAFs (Supplementary Fig. 2f). We observed
three distinct classes of dynamic CAF-CC interactions on CDMs:
(i) static interactions where t-RFP-CAFs and GFP-CCs remain in
close proximity without migrating (Supplementary Fig. 2g (i));
(ii) CAF-driven migration where movement of a group of CCs is
directed by the CAFs (Supplementary Fig. 2g (ii) and (iii)) and
parallel migration where CAFs and CCs stream together in a
parallel direction (Supplementary Fig. 2g (iii)). Scoring of these
interactions revealed that fl-e-CAFs and fl-CCs mainly follow the
static interactions, while fl-CCs seeded with mt-e-CAFs use CAF-
driven migration and parallel migration during streaming
(Supplementary Fig. 2h). This suggests that mt-e-CAFs directly
interact with fl-CCs to promote their collective movement,
partially explaining the effects observed in 3D matrices (Fig. 2d,
e), and in line with previous work48,56. Conversely, mt-CCs
streaming in the presence of their corresponding mt-e-CAFs
relied primarily on CAF-driven migration and parallel migration,
while static interactions only occurred in the presence of fl-e-
CAFs (Supplementary Fig. 2h).
We next interrogated whether long-range interactions between
CAFs and CCs can also influence cancer cell invasion. Collagen
matrices were generated using fl-e-CAFs and mt-e-CAFs as
before, after which CAFs were pharmacologically removed
(Fig. 2f, h). CCs were then seeded and allowed to invade into
the collagen matrix, while fl-e-CAFs or mt-e-CAFs were seeded
under the metal grid in order to expose invading CCs to media
continuously conditioned by CAFs (Fig. 2f, h). Invasion of fl-CCs
or mt-CCs into matrices originally made using fl-e-CAFs that
were subsequently removed, was increased upon exposure to
media continually conditioned by mt-e-CAFs compared to fl-e-
CAFs (Fig. 2g and Supplementary Fig. 2i with DMEM control).
On matrices originating from mt-e-CAFs that have subsequently
been removed, media conditioned by mt-e-CAFs also increased
fl-CC invasion (Fig. 2i); however, it did not significantly alter mt-
CC invasion (Fig. 2i). This suggests that mt-e-CAFs can also
signal to fl-CCs in a long-range manner to render them more
invasive in both poorly remodeled and more permissive collagen
matrices.
While GOF mutant p53 in the cancer cell compartment
has previously been shown to drive a pro-invasive
program4,8,17,18,52,53,57,, our results using long-range condition-
ing, CAF-based organotypic assays and cell streaming experi-
ments reveal that mt-e-CAFs can induce fl-CC invasion by
creating an environment more favorable to invasion, via direct
contact and through long-range, paracrine interactions.
mt-CCs support fl-CC invasion through less-permissive
environments. Given the heterogeneity found in PC cells5,9, we
next sought to assess how fl-CCs and mt-CCs, which can both
reside in the same tumor37,58, may influence the invasive beha-
vior of one another. We allowed fl-CCs alone, mt-CCs alone or a
mosaic mix of fl-CCs and mt-CCs (1:1 ratio) to invade into
collagen matrices originally created by fl-e-CAFs or by mt-e-
CAFs (Fig. 3a). We observed that in matrices generated by fl-e-
CAFs or by mt-e-CAFs, invasion of fl-CCs was increased in the
presence of mt-CCs compared to fl-CCs alone (Fig. 3b (i)). mt-
Fig. 1 Isolation and characterization of CAFs from KPflC and KPC primary tumors. a Representation of isolation of cancer cells and CAFs from poorly
metastatic KPflC (top panel) and highly metastatic KPC (lower panel) primary tumors using the previously generated LSL-E-cadherin-GFP mouse.
b Brightfield and GFP imaging of cancer cells and CAFs isolated from E-Cadherin-GFP-KPflC tumors and from E-Cadherin-GFP-KPC tumors. Scale bar:
100 μm. c Immunocytochemistry staining of markers of CAF activation (ACTA2 α-smooth muscle actin; FAP fibroblast activated protein) in fl-e-CAFs and
mt-e-CAFs. Scale bar: 100 μm. d Immunofluorescence staining of CAFs and cancer cells for markers of pancreatic epithelial cells (E-cadherin, keratin 19).
Scale bar: 100 μm. e Representation of CAF-driven contraction assay. f Representative images of CAF-collagen matrices and quantification of matrix area
following a 12-day contraction assay. Scale bar: 1 cm, n= 3 biological repeats with three technical replicates per biological repeat. g Shear rheology
measurements of storage modulus of matrices remodeled by fl-e-CAFs or by mt-e-CAFs and normalized to values found in fl-e-CAFs matrices. n= 3
biological repeats with three technical replicates per biological repeat. h Polarized light imaging and quantification of picrosirius red-stained collagen
matrices remodeled by fl-e-CAFs or by mt-e-CAFs. Scale bar: 100 μm, n= 3 biological repeats with three technical replicates per biological repeat.
i Representative maximum projections of Second Harmonic Generation (SHG) signal in collagen matrices remodeled by fl-e-CAFs and by mt-e-CAFs and
quantification of SHG signal intensity through a 60 μm z-stack and at intensity peak (bar graph inset). Scale bar: 100 μm, n= 3 biological repeats with three
technical replicates per biological repeat. j Representative single-plane SHG images of collagen matrices generated by fl-e-CAFs or by mt-e-CAFs and
quantification of GLCM correlation (bar graph inset depicts GLCM mean correlation normalized to mean correlation found in fl-e-CAFs matrices). Scale
bar: 100 μm, n= 3 biological repeats with three technical replicates per biological repeat. k Representative images of picrosirius red staining imaged with
brightfield or polarized light and quantification of collagen birefringence signal in primary KPflC and KPC tumors. n= 7 for KPflC tumors and n= 9 for KPC
tumors. Data are presented as mean values with SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10968-6
4 NATURE COMMUNICATIONS |         (2019) 10:3637 | https://doi.org/10.1038/s41467-019-10968-6 | www.nature.com/naturecommunications
CC invasion was not significantly affected by the presence of fl-
CCs in either type of matrix (Fig. 3b (ii)).
We also observed that fl-CCs followed three distinct modes of
invasion; (i) as fl-CC-only clusters (Fig. 3c (i)), (ii) fl-CCs in
clusters with mt-CCs (Fig. 3c (ii) or (iii) as single cells (Fig. 3c
(iii)). Scoring of these distinct patterns of invasion demonstrated
that in non-permissive fl-e-CAF matrices, fl-CCs most notably
rely on forming clusters with mt-CCs to invade, while they
predominantly invaded as single cells when seeded on a
permissive mt-e-CAF matrix (Fig. 3d). This suggests that in
non-permissive matrices (Fig. 2d, e), mt-CCs can act as carriers
for the otherwise poorly invasive fl-CCs. However, fl-CCs do not
need to interact with mt-CCs when invading into the invasion-
permissive matrices remodeled by mt-e-CAFs.
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Guided by the observed increase of cancer cell invasion upon
interactions with mt-e-CAFs, we investigated how CC-CAF
crosstalk influences cancer cell invasive behaviors in vivo.
CAF-cancer cell crosstalk drives invasion and metastasis
in vivo. fl-CCs or mt-CCs were subcutaneously injected with
either fl-e-CAFs or mt-e-CAFs into the rear flank of Balb/c-
Fox1nuAusb mice (Fig. 3e). A 1:3 ratio of CC:CAF was used to
mimic the high stromal content and low tumor cellularity com-
monly found in PDAC25. Co-injection of either fl-e-CAFs or mt-
e-CAFs with fl-CCs or mt-CCs did not significantly affect tumor
growth (Supplementary Fig. 3a). Analysis of local invasion
revealed that fl-CCs co-injected with fl-e-CAFs formed encap-
sulated tumors with well-defined margins; while fl-CCs and mt-
CCs co-injected with mt-e-CAFs displayed increased invasion
into surrounding tissue (Fig. 3f, g, Supplementary Fig. 3b and
Methods for details on scoring of local invasion25). mt-CCs
readily invaded into the surrounding tissue when injected with fl-
e-CAFs or mt-e-CAFs (Fig. 3f, g). In agreement with our findings
in contraction assays and in autochthonous pancreatic tumors
(Fig. 1h, k), we also observed an increase of collagen birefringence
in tumors generated by fl-CCs and mt-CCs co-injected with
mt-e-CAFs compared to co-injection with fl-e-CAFs (Supple-
mentary Fig. 3c). Given that ECM remodeling plays a critical role
in driving cancer cell motility2,22,49,59, this may partially explain
the enhanced invasiveness of fl-CCs and mt-CCs in the presence
of mt-e-CAF compared to fl-e-CAF.
Next, the long-term effects of interactions between CAFs and
cancer cells on metastasis and survival were assessed using
orthotopic co-injections of cancer cells expressing luciferase with
CAFs expressing t-RFP into the pancreas of NOD/SCID/ILR2γ−/−
mice (Fig. 3h). Tumor progression was monitored via twice-
weekly IVIS Luciferase imaging22,60. Metastatic burden and
occurrence of ascites were increased (percent of mice with ascites
at endpoint: fl-CCs+ fl-e-CAFs: 0%, fl-CCs+mt-e-CAFs: 40%,
mt-CCs+ fl-e-CAFs: 50%, and mt-CCs+mt-e-CAFs: 100%),
and survival was reduced when fl-CCs or mt-CCs were co-
injected with mt-e-CAFs compared to fl-e-CAFs (Fig. 3i–k),
indicating that mt-e-CAFs facilitate metastatic spread for both fl-
CCs and mt-CCs. Staining for t-RFP in tumors at endpoint
demonstrated that both fl-e-CAFs and mt-e-CAFs are maintained
(Supplementary Fig. 4a), highlighting their continued role during
cancer progression in this setting. In addition, metastatic burden
in the liver and the lungs at endpoint was enhanced for fl-CCs co-
injected with mt-e-CAFs compared to fl-e-CAFs and was not
significantly different for mt-CCs when co-injected with either fl-
e-CAFs or mt-e-CAFs (Supplementary Fig. 4b, c). Lastly, we
confirmed that the increase of metastatic burden and the reduced
survival were not a result of changes in the proliferation rate of
cancer cells upon co-injection with CAFs by quantifying the
in vivo luciferase signal at the early stages of cancer progression
(Fig. 3h–k and Supplementary Fig. 4d) and by measuring the
in vitro doubling time of cancer cells co-cultured with fl-e-CAFs
or mt-e-CAFs (Supplementary Fig. 4e).
In order to identify factors potentially responsible for the
enhanced invasion and metastatic spread observed in the
presence of mt-e-CAFs, we next profiled the secretome of CAFs
isolated from the poorly-metastatic KPflC and the highly-
metastatic KPC models.
HSPG2 is secreted by mt-e-CAFs and drives metastasis. Mass-
spectrometry analysis of the CAF secretomes using CM identified
19 proteins classed as secreted or extracellular proteins with
significantly different levels of expression between fl-e-CAFs and
mt-e-CAFs (Fig. 4a, Supplementary Fig. 5a and Supplementary
Data 1). In particular, secretion of heparan sulphate proteoglycan
2 (HSPG2, or perlecan) was found to be increased in mt-e-
CAF CM compared to fl-e-CAF CM, and this was confirmed
using RT-qPCR and IHC staining in CAF-collagen matrices using
both early and late passages of CAFs (Fig. 4b, c and Supple-
mentary Fig. 5b). We therefore investigated the role of HSPG2 in
establishing the pro-invasive and pro-metastatic environment
created by mt-e-CAFs. HSPG2 is a multifunctional proteoglycan
found in the ECM of most organs61. In prostate and oral squa-
mous cancer, HSPG2 can play a role in fibrosis, cancer cell
growth, angiogenesis, cell invasion and response to anti-cancer
agents62; however, its role in PC has not been explored so far.
In order to evaluate the functional role of mt-e-CAF-derived
HSPG2, we used CRISPR-Cas9 to knockout (KO) HSPG2 in mt-
e-CAFs63. The efficacy of CRISPR-Cas9 editing of HSPG2 in a
mixed population of mt-e-CAFs KO HSPG2 was confirmed using
a T7 endonuclease 1 (T7E1) assay (Fig. 4d) and via IHC analyses
(Fig. 4e). We initially used the mixed population of mt-e-CAFs
KO HSPG2 to assess the effect of partial reduction of HSPG2
deposition on cancer cell invasion. fl-CCs and mt-CCs were
seeded onto matrices generated by mt-e-CAFs WT or by a mixed
population of mt-e-CAFs KO HSPG2 and allowed to invade. As
before, both fl-CCs and mt-CCs readily invaded into mt-e-CAFs
WT remodeled matrices (Fig. 4f, purple bars). In matrices
remodeled by the mixed population of mt-e-CAFs KO HSPG2 we
observed a reduction in invasion by fl-CCs and a larger reduction
in invasion by mt-CCs (Fig. 4f, brown bars). Next, we injected
Fig. 2mt-cells further potentiate fl-e-CAFs and mt-e-CAFs to induce fl-CCs invasion. a Representation of (i) local crosstalk between cancer cells and CAFs,
(ii) long-range CC driven interactions, and (iii) long-range CAF-driven interactions between cancer cells and CAFs across a primary pancreatic tumor.
b Top panel: representation of media conditioning driven by cancer cells or by CAFs and treatment of fl-e-CAFs with conditioned media (CM) during
remodeling of a collagen matrix over 12 days. Lower panel: representative images and quantification of collagen birefringence in fl-e-CAFs matrices treated
with CM generated by fl-e-CAFs, mt-e-CAFs, mt-CCs or fl-CCs, and normalized to treatment with CM from fl-e-CAFs. Scale bar: 100 μm. c Top panel:
representation of media conditioning driven by cancer cells or by CAFs and treatment of mt-e-CAFs with CM during remodeling of a collagen matrix over
12 days. Lower panel: representative images and quantification of collagen birefringence in mt-e-CAFs matrices treated with CM generated by mt-e-CAFs,
fl-e-CAFs, mt-CCs or fl-CCs, and normalized to treatment with CM from mt-e-CAFs. Scale bar: 100 μm. d Schematic representation of 3D CAF-based
organotypic invasion assay. e Representative H&E staining of organotypic invasion assay and quantification of invasive index for fl-CCs or mt-CCs invading
into fl-e-CAF matrices (blue bars) or into mt-e-CAFs matrices (purple bars). Scale bar: 200 μm. f Schematic representation of 3D organotypic invasion
assay including pharmaceutical removal of CAFs following matrix establishment and continuous media conditioning driven by CAFs during cancer cell
invasion. g Quantification of invasive index and representative images of H&E stained organotypic matrices with fl-CCs and mt-CCs invading into matrices
generated by fl-e-CAFs and with continuous media conditioning driven by fl-e-CAFs or by mt-e-CAFs during invasion. Scale bar: 200 μm. h Schematic
representation, i quantification of invasive index and representative images of H&E stained organotypic matrices with fl-CCs and mt-CCs invading into
matrices generated by mt-e-CAFs and with continuous media conditioning driven by fl-e-CAFs or by mt-e-CAFs during cancer cell invasion. Scale bar:
200 μm. Contraction and invasion assays were conducted in three biological repeats with three technical replicates per biological repeat. Individual data
points are presented with mean values and SEM. *p < 0.05
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fl-CCs or mt-CCs with mt-e-CAFs KO HSPG2 orthotopically
(Fig. 4g). We compared metastatic burden and survival to the
original orthotopic model using mt-e-CAFs WT (Fig. 3h–k). This
revealed that survival was enhanced and metastatic burden was
reduced in the presence of mt-e-CAFs KO HSPG2 compared to
mt-e-CAFs WT for both fl-CCs and mt-CCs, with a more
pronounced effect for mt-CCs (Fig. 4g–i). Metastatic burden in
the liver at endpoint was reduced for both cancer cell types
injected with mt-e-CAFs KO HSPG2 compared to mt-e-CAFs
WT (Fig. 4j), while mice injected with mt-CCs also developed
lung metastases (Supplementary Fig. 5c). The observed reduction
of metastatic burden upon loss of stromal HSPG2 was not due to
initial changes in cancer cell proliferation, as assessed by
quantifying the in vivo luciferase signal and the in vitro doubling
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time of cancer cells co-cultured with CAFs (Supplementary
Fig. 5d, e).
We next isolated clonal populations from the mt-e-CAF KO
HSPG2 population, and complete loss of HSPG2 was confirmed
in two clones, #10 and #18, via genomic sequencing and IHC
(Supplementary Fig. 6a-c). Invasion of both fl-CCs and mt-CCs
into matrices remodeled by mt-e-CAF KO HSPG2 clones #10 and
#18 was significantly reduced compared to mt-e-CAF WT
matrices (Fig. 5a). Importantly, the reduction of cell invasion in
matrices generated by mt-e-CAF KO HSPG2 clones #10 and #18
was more severe than in matrices generated by the mixed mt-e-
CAF KO HSPG2 population (Fig. 4f versus Fig. 5a), demonstrat-
ing a dose-dependent effect of stromal HSPG2 manipulation on
cancer cell invasion.
Lastly, we used CRISPR interference (KRAB-dCas9) to repress
HSPG2 expression in the mt-e-CAFs. Reduced HSPG2 expression
in mt-e-CAFs was confirmed via RT-qPCR and IHC analyses
(Fig. 5b, c). The ability of fl-CCs and mt-CCs to invade into
matrices with reduced HSPG2 deposition was decreased com-
pared to invasion into matrices remodeled by mt-e-CAFs WT
(Fig. 5d, e), thereby validating our initial finding (Fig. 4f and
Fig. 5a).
While mt-CCs can readily invade into less-permissive matrices
established by fl-e-CAFs (Fig. 2d, e), we found a reduction of mt-
CC invasion when seeded onto matrices generated by mt-e-CAFs
KO HSPG2 (Figs. 4f and 5a). It is possible that mt-CCs can
educate fl-e-CAFs to secrete more HSPG2 during invasion assays
(12 days), while modulation of HSPG2 cannot be achieved with
CAFs that have been genetically engineered to suppress HSPG2
expression.
Collectively, we demonstrate that enhanced HSPG2 secretion
by mt-e-CAFs is a key driver of the establishment of an
environment permissive to cell invasion and metastasis in both
in vitro and in vivo models.
Paracrine signaling mediated by NFκB induces HSPG2
expression. We next performed microarray transcript expression
profiling and Gene Set Enrichment Analysis (GSEA) of fl-CCs
and mt-CCs in order to identify genes that could trigger HSPG2
expression in CAFs in a paracrine manner (Supplementary
Fig. 7a, b, Supplementary data 2 and GEO accession number
GSE123646). Among the genes that were differentially regulated
between fl-CCs and mt-CCs, we found that expression of NFκB-
signaling pathway components such as TNFα signaling were
enhanced in mt-CCs compared to fl-CCs (Fig. 6a and Supple-
mentary Fig. 7c, d)64. Considering that NFκB signaling can
induce HSPG2 expression in a paracrine manner65, we next
assessed whether increased NFκB signaling in mt-CCs could be a
driver of increased production of HSPG2 by CAFs.
Increased activation of the NFκB pathway in mt-CCs
compared to fl-CCs was confirmed using multiplexed analysis
of canonical NFκB signaling66, and this was mirrored in their
matched CAFs (Fig. 6b quantified in c). This aligns with the
enhanced secretion of HSPG2 observed in mt-e-CAFs compared
to fl-e-CAFs (Fig. 4a-c). Similarly, WB analyses of pIκαB(S32) in
cancer cells and their matched CAFs (Fig. 6d) as well as ELISA
analysis of TNFα secretion (Fig. 6e) confirmed that NFκB
signalling is upregulated in mt-cells compared to fl-cells67. To
functionally test the paracrine signaling between CCs and CAFs,
we next stimulated fl-e-CAFs with TNFα and found that NFκB
signaling was induced upon treatment, to a similar level as for mt-
e-CAFs at baseline (Fig. 6f–h). Next, RT-qPCR analysis
demonstrated that HSPG2 expression is increased in fl-e-CAFs
upon treatment with TNFα (Fig. 6i).
Together, this data suggest that paracrine signaling between
cancer cells and the surrounding fibroblasts in tumors with a
GOF mutant p53 is partly mediated by enhanced NFκB signaling,
and this can stimulate HSPG2 expression and deposition in the
ECM (Fig. 6j).
Lastly, stromal deposition of HSPG2 in a cohort of KPflC and
KPC pancreatic tumors was assessed via IHC staining. Quanti-
fication of HSPG2 staining in stromal areas revealed that HSPG2
deposition in the stroma is increased in KPC tumors compared to
KPflC tumors (Fig. 6k and Supplementary Fig. 7e). This confirms
that in the GEMM setting, HSPG2 deposition is enhanced in the
stroma of native pancreatic tumors hosting cancer cells with a
GOF mutant p53 compared to null p53.
mt-e-CAFs reduce chemotherapy efficacy. The role played by
the tumor stroma2, particularly CAFs28,32,68,69 in tumor cell
response to chemotherapy is becoming increasingly apparent. We
therefore used IHC to assess the response of fl-CCs and mt-CCs
to standard-of-care gemcitabine/Abraxane treatment during
invasion into matrices containing fl-e-CAFs or mt-e-CAFs22,60.
In fl-e-CAF remodeled matrices, gemcitabine/Abraxane reduced
cell proliferation (Fig. 7a) and enhanced cell apoptosis (Fig. 7b)
for both fl-CCs and mt-CCs, in line with the use of gemcitabine/
Abraxane in the clinical setting70. Conversely in mt-e-CAF
remodeled matrices, cell proliferation was not significantly
decreased (Fig. 7c) and cell apoptosis was not significantly
increased for either fl-CCs or mt-CCs (Fig. 7d) after treatment
with gemcitabine/Abraxane compared to control. This implies
that cancer cell response to chemotherapy can be modulated by
Fig. 3 mt-CCs act as carrier for fl-CCs and mt-e-CAFs drive local invasion and metastasis in vivo. a Schematic representation of 3D organotypic invasion
assays with mosaic cancer cell cultures invading into matrices generated by fl-e-CAFs or mt-e-CAFs, b representative images of p53 staining (PAb421
antibody) and quantification of invasive index of (i) fl-CCs and (ii) mt-CCs invading alone or in a mosaic culture (fl-CCs+mt-CCs 50:50 ratio) into fl-e-
CAF matrices or into mt-e-CAF matrices. Scale bar: 200 μm, n= 3 biological repeats with three technical replicates per biological repeat. c Representative
images and schematic representation of p53 staining (PAb421 antibody) in organotypic matrices and depicting fl-CCs invading either as a cluster of fl-CCs
only (i), as a mosaic cluster with mt-CCs (ii) or as single fl-CCs (iii). Scale bar: 200 μm. d Quantification of the mode of invasion followed by fl-CCs during
invasion into fl-e-CAF matrices or into mt-e-CAF matrices and in the presence or absence of mt-CCs, n= 3 biological repeats with three technical
replicates per repeat. e Schematic representation of subcutaneous injection of cancer cells (25%) with CAFs (75%), tumor growth and mouse euthanasia
followed by tissue collection. f Representative H&E images, and g quantification of mean maximum score of cancer cell local invasion into the surrounding
tissue in subcutaneous xenografts generated by fl-CCs injected with fl-e-CAFs (orange dots, n= 5 mice) or injected with mt-e-CAFs (brown dots, n= 4
mice) and in subcutaneous xenografts generated by mt-CCs injected with fl-e-CAFs (blue dots, n= 5 mice) or with mt-e-CAFs (green dots, n= 5 mice).
Scale bar: 200 μm. h Schematic representation of orthotopic (in pancreas) injection of 50 luciferase-expressing CCs (fl-CCs or mt-CCs) with 150 CAFs
(fl-e-CAFs or mt-e-CAFs) and IVIS whole body monitoring of tumor growth and metastatic spread. i Representative images of whole body IVIS imaging
in mice bearing orthotopic xenografts, and j Kaplan–Meier survival analysis of time to metastasis and of k survival of mice orthotopically injected with
fl-CCs+ fl-e-CAFs (n= 5 mice); fl-CCs+mt-e-CAFs (n= 5 mice); mt-CCs+ fl-e-CAFs (n= 6 mice) or with mt-CCs+mt-e-CAFs (n= 4 mice). Individual
data points are presented with mean values and SEM. *p < 0.05
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10968-6
8 NATURE COMMUNICATIONS |         (2019) 10:3637 | https://doi.org/10.1038/s41467-019-10968-6 | www.nature.com/naturecommunications
the local CAF-generated microenvironment, or by changes in
matrix stiffness59 (Fig. 1g and Supplementary Fig. 1d, e).
To assess whether direct contact between CAFs and cancer
cells influenced response to chemotherapy, we seeded CCs and
CAFs onto dishes coated with collagen and measured cell
response to gemcitabine/Abraxane using IHC analyses (Supple-
mentary Fig. 8). For fl-CCs seeded alone or in co-culture with fl-
e-CAFs, cell proliferation was decreased and cell apoptosis was
increased upon a 24 h exposure to gemcitabine/Abraxane
(Supplementary Fig. 8a, b). However no significant changes of
cell proliferation and cell apoptosis were observed in fl-CCs
seeded with mt-e-CAFs and treated with gemcitabine/Abraxane
for 24 h (Supplementary Fig. 8a, b). Similarly, cell proliferation
was decreased and cell apoptosis was increased upon treatment
with gemcitabine/Abraxane in mt-CCs seeded alone or with fl-e-
CAFs. However, no significant change of cell proliferation and
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cell apoptosis were observed for mt-CCs seeded with mt-e-CAFs
(Supplementary Fig. 8c, d).
Together, this demonstrates that mt-e-CAFs impair cancer cell
response to gemcitabine/Abraxane (irrelevant of the cancer cell
p53 status) by creating a protective environment but also via
direct interactions with the cancer cells.
Although these IHC markers provide initial insights into
cancer cell response to treatment, these fixed endpoints lack the
ability to monitor single-cell behavior longitudinally in vivo. We
recently employed a CDK1-FRET biosensor as a dynamic readout
of cell response to gemcitabine/Abraxane with single-cell
resolution in living mice (Fig. 7e22,71–73). The serine/threonine
kinase Cyclin-dependent kinase 1 (CDK1) is a critical component
of the complexes responsible for phosphorylating and activating
target substrates controlling cell cycle progression. CDK1 is
specifically activated in G2/M and monitoring its activity can be
used as a surrogate indicator of cell cycle progression in response
to gemcitabine/Abraxane22,71,72. In the fluorescence lifetime color
map, high CDK1 activity (FRET) in response to gemcitabine/
Abraxane treatment is shown by lower mCerulean lifetimes and
blue/green colors, while low CDK1 activity (no FRET) is
represented by longer mCerulean lifetimes and red/yellow colors
(Fig. 7e).
We used the CDK1 biosensor as a readout of response to
gemcitabine/Abraxane for fl-CCs and mt-CCs seeded with fl-e-
CAFs or mt-e-CAFs on dishes coated with collagen. In agreement
with earlier findings using IHC (Supplementary Fig. 8), CDK1
activity was increased after 24 h of treatment with gemcitabine/
Abraxane for fl-CCs seeded alone or with fl-e-CAFs; however,
there was no significant change of CDK1 activity for fl-CCs
seeded with mt-e-CAFs and treated with gemcitabine/Abraxane
for 24 h (Fig. 7g quantified in Fig. 7h, i). Similarly, while CDK1
activity was increased upon a 24 h treatment with gemcitabine/
Abraxane in mt-CCs seeded alone or with fl-e-CAFs, there was
no significant change of CDK1 activity in mt-CCs seeded with
mt-e-CAFs and treated with gemcitabine/Abraxane for 24 h
(Fig. 7j quantified in Fig. 7k, l).
We next used titanium optical windows to monitor cancer cell
response to gemcitabine/Abraxane longitudinally in the presence
of fl-e-CAFs or mt-e-CAFs within live tumors. As previously, CCs
were co-injected with CAFs into the rear flank of Balb/c-
Fox1nuAusb mice (Fig. 8a). Once tumors were fully established
(average tumor volume: 100 mm3), optical titanium imaging
windows were surgically implanted74,75, mice were administered
with a single dose of gemcitabine/Abraxane on day 3 post-surgery
(Fig. 8a) and imaging of CDK1 activity in cancer cells was
performed over three days post-treatment (Fig. 8a). This revealed
a sustained activation of CDK1 in fl-CCs at 24 h, 48 h, and 72 h
after treatment with gemcitabine/Abraxane in tumors formed by
fl-CCs co-injected with fl-e-CAFs (Fig. 8b (i)). This increase of
CDK1 activity was only observed 72 h after treatment with
gemcitabine/Abraxane in tumors formed by fl-CCs co-injected
with mt-e-CAFs (Fig. 8b (ii)), revealing a delay of cancer cell
response to chemotherapy in the presence of mt-e-CAFs in live
tumors. Similarly, for tumors formed by mt-CCs injected with fl-
e-CAFs, CDK1 activation was observed at 24 h, 48 h, and 72 h
after treatment with gemcitabine/Abraxane (Fig. 8c (i)), however
CDK1 activation only occurred after 72 h of treatment with
gemcitabine/Abraxane in tumors generated by mt-CCs injected
with mt-e-CAFs (Fig. 8c (ii)). Importantly, mt-e-CAFs KO
HSPG2 did not significantly alter fl-CC response to gemcitabine/
Abraxane over time compared to mt-e-CAFs WT (Fig. 8b (iii)).
On the other hand, mt-CC response to gemcitabine/Abraxane
occurred earlier when co-injected with mt-e-CAFs KO HSPG2
(CDK1 activation now at 24 h post-treatment, Fig. 8c (iii)).
This prompted us to assess whether long-term survival could
also be improved in this setting. mt-CCs were subcutaneously
injected with mt-e-CAFs WT or mt-e-CAFs KO HSPG2. Once
tumors were established, mice were subjected to cycled admin-
istration of saline control or gemcitabine/Abraxane, until reach-
ing experimental endpoint (Fig. 9a). Tumor growth was reduced
and time to experimental endpoint (maximum tumor volume)
was increased upon reduced deposition of stromal HSPG2 and in
response to gemcitabine/Abraxane (Fig. 9b, c; compare gemcita-
bine/Abraxane in mt-CCs+mt-e-CAFs WT (green line) vs
gemcitabine/Abraxane in mt-CCs+mt-e-CAFs KO (red line)).
To further assess how reduction of HSPG2 in the stroma affects
survival upon treatment with gemcitabine/Abraxane, we ortho-
topically injected mice with mt-CCs expressing luciferase in
combination with either mt-e-CAFs WT or with mt-e-CAFs KO
HSPG2. Once tumors were confirmed via IVIS imaging, mice
were subjected to cycles of treatment with gemcitabine/Abraxane
twice weekly (Fig. 9d). Similar to our findings using subcutaneous
xenografts, we observed a prolonged time to experimental
endpoint for mice injected with mt-e-CAFs KO HSPG2 (red)
compared to mt-e-CAFs WT (green) upon treatment with
gemcitabine/Abraxane (Fig. 9d, e). While in previous experiments
we used IVIS imaging to determine experimental endpoint
(Fig. 4h), here endpoint was reached when mice showed clinical
signs of illness. This could explain the observed differences in
time to experimental endpoints (Fig. 4h vs Fig. 9e). Together, our
data demonstrate that reduced response to gemcitabine/Abraxane
in the presence of mt-e-CAFs can be partly driven by HSPG2.
This also suggests that targeting of stromal HSPG2 could
potentially increase the efficacy of standard-of-care
chemotherapy.
Collectively, this data demonstrate that interactions between
cancer cells and mt-e-CAFs delay CC response to standard-of-
Fig. 4 HSPG2 is a critical component of the permissive environment created by mt-e-CAFs. a Volcano plot depicting proteins differently secreted by fl-e-
CAFs (left) and by mt-e-CAFs (right), n= 5 biological repeats. b. RT-qPCR analysis of HSPG2 mRNA levels in fl-e-CAFs and mt-e-CAFs, n= 3 biological
repeats. c HSPG2 IHC staining and quantification of optical density of staining in collagen matrices remodeled by fl-e-CAFs and by mt-e-CAFs. Scale bar:
25 μm, n= 3 biological repeats with three technical replicates per biological repeat. d T7E1 assay at the HSPG2 locus in mt-e-CAFs WT and in a mixed
population of mt-e-CAFs KO HSPG2. e HSPG2 IHC staining and quantification of optical density in collagen matrices remodeled by mt-e-CAFs WT or mt-
e-CAFs KO HSPG2. Scale bar: 100 μm, n= 3 biological repeats with three technical replicates per biological repeat. f Representative H&E stained sections
and quantification of invasive index for fl-CCs and mt-CCs invading into matrices remodeled by mt-e-CAFs WT or by mt-e-CAFs KO HSPG2. n= 3
biological repeats with three technical replicates per biological repeat. Scale bar: 100 μm. g Kaplan–Meier survival analysis of time to metastasis and
Kaplan–Meier analysis of survival in mice orthotopically injected with fl-CCs+mt-e-CAFs WT (n= 5 mice, data shown in Fig. 3j-k) or with fl-CCs+mt-e-
CAFs KO HSPG2 (n= 6 mice). h Kaplan–Meier survival analysis of time to metastasis and Kaplan–Meier analysis of survival in mice orthotopically injected
with mt-CCs+mt-e-CAFs WT (n= 4 mice, data shown in Fig. 3j-k) or with fl-CCs+mt-e-CAFs KO HSPG2 (n= 6 mice). i Table summarizing mean time
to metastasis and mice with metastasis at endpoint, and j number of liver metastases for mice orthotopically injected with fl-CCs+mt-e-CAFs WT, fl-CCs
+mt-e-CAFs KO HSPG2, mt-CCs+mt-e-CAFs WT or mt-CCs+mt-e-CAFs KO HSPG2. Individual data points are presented with mean values and SEM.
*p < 0.05, **p < 0.01, ***p < 0.001
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care chemotherapy, and this is partly influenced by HSPG2 for
mt-CCs but not for fl-CCs. This highlights a potential TP53
alteration-specific interaction between cancer cells and CAFs that
governs response to chemotherapy.
Discussion
PC development often relies on the establishment of a fibrotic
stroma, which leads to aberrant interactions between cancer cells
and stromal compartments2. Studies assessing stromal manip-
ulation have highlighted how the pancreatic stroma, and in
particular CAFs, play multiple, and often conflicting roles in
driving disease progression32,34,36,37. While the molecular land-
scape of PC has been shown to be highly heterogeneous5, recent
work has revealed the existence of distinct CAF populations with
heterogeneous histologic, epigenetic, immunologic, and
mechanical signatures within pancreatic tumors30,37.
Here, we generated CAFs from end-stage, poorly-metastatic
KPflC and highly-metastatic KPC GEMMs of PC to interrogate
how alterations in TP53, one of the most commonly altered genes
in cancer, differently shape the pancreatic stroma. We reveal that
CAFs educated by cancer cells with a GOF mutant p53 govern the
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establishment of an environment permissive to invasion and
metastasis for GOF and null p53 cancer cells alike (Fig. 9f (i)).
We identified and validated HSPG2 as a critical component of
the pro-metastatic environment created by mt-e-CAFs (Fig. 9f
(i)). Our results indicate that reducing stromal deposition of
HSPG2 impairs the ability of both fl-CCs and mt-CCs to invade
into the surrounding matrix and spread to distant sites. The
observed decrease of metastasis upon loss of stromal HSPG2 may
potentially be due to disrupted cell adhesion or compromised
integrin signaling, which can be regulated by HSPG226,51,65,76,77.
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In addition, our data reveal that mt-CCs signal to the sur-
rounding fibroblasts and induce HSPG2 expression in the stroma
in a paracrine manner, which is partly mediated by NFκB sig-
naling. This aligns with recent work in prostate cancer65, and
suggests that targeting NFκB paracrine signaling could also be
used in the future to disrupt stromal education driven by PC cells
with a GOF mutant p53.
Interrogating the interactions between distinct cancer cells and
CAFs demonstrated that fl-e-CAFs can be reprogrammed by
interacting with mt-CCs or with mt-e-CAFs, leading to the
acquisition of more invasive and metastatic features (Fig. 9f (ii)).
In addition, using mosaic cultures of fl-CCs and mt-CCs, we
found that invasive mt-CCs can act as a carrier for poorly invasive
fl-CCs to increase their invasiveness in non-permissive environ-
ments (Fig. 9f (iii)). This is potentially mediated by the ability of
mt-CCs to educate fl-e-CAFs to create a more permissive envir-
onment (Fig. 2b). It is also possible that the highly invasive mt-
CCs create tracks in matrices generated by fl-e-CAFs, which can
subsequently be followed by fl-CCs56. Our data suggest that
within pancreatic tumors hosting heterogeneous subpopulations
of cancer cells and CAFs, pro-invasive phenotypes can be trans-
ferred to less aggressive cells across the tumor to increase invasion
and metastasis, and to impair response to chemotherapy.
Lastly, we revealed that mt-e-CAFs provide cancer cells with
stromal cues to delay and reduce response to gemcitabine/
Abraxane, which could be reverted by reducing HSPG2 stromal
deposition for mt-CCs (Fig. 9f (iv)). This highlights a p53-
dependent interaction between cancer cells and CAFs during
response to gemcitabine/Abraxane. This also suggests that com-
bining biomarkers of GOF mutant p53 in the cancer cell com-
partment with high HSPG2 stromal deposition may be used in
the future to identify patients that could benefit from HSPG2
manipulation in combination with chemotherapy. Considering
that HSPG2 secretion in the stroma is partly mediated by NFκB
signaling, our findings warrant further consideration to repur-
posing anti-NFκB drugs that are currently used in the clinic78–80.
We propose that rather than completely inhibiting stroma-
cancer cell feedback, specific manipulation of CAF subpopula-
tions that have been educated by cancer cells harboring a GOF
mutant p53 can impair metastasis while maintaining the anti-
tumorigenic functions of the PC stroma.
Methods
Study design. Organotypic contraction and invasion assays as well as CDM
−based experiments were performed in three independent biological repeats, with
three technical replicates per repeat and per group. The numbers of mice used for
each experiment are outlined in their corresponding figure legends. CDK1 activity
was assessed via FLIM-FRET measurements in >40 cells per technical replicate or
per mouse. IHC, SHG, picrosirius red, and GLCM analyses were conducted on
three regions of interest in organotypic matrices and in five representative fields of
view in subcutaneous xenograft and autochthonous experiments. Secretome ana-
lysis by mass spectrometry was performed on 4–5 biological replicates. Endpoints
for animal experiments were defined according to Garvan Ethics Committee
guidelines (16/13 protocol).
Statistical analysis. Unpaired two-group comparisons were performed using the
Mann–Whitney U test, unpaired multi-group comparisons by the Kruskal–Wallis
test, and Kaplan–Meier curves were compared using the Mantel–Cox log-rank test.
Where multiple tests were performed, familywise error rate was controlled by the
Holm-Sidak step-up method. GraphPad Prism v7 was used for all procedures.
Summary data in figures are presented as mean values with standard error of the
mean (SEM), with asterisks used as a guide to statistical significance, as *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
Animals. Animal experiments were performed following the Australian code of
practice for the care and use of animals for scientific purposes and in compliance
with Garvan Ethics Committee guidelines (16/13 protocol), with genotyping of
GEMMs performed by Garvan Molecular Genetics facility (Sydney, Australia).
Establishment of cell lines and cell culture. Primary mt-CCs were isolated from
Pdx1-Cre, LSL-K-rasG12D/+, LSL-Trp53R172H/+ tumors; primary fl-CCs were iso-
lated from Pdx1-Cre, LSL-K-rasG12D/+, LSL-Trp53fl/+ tumors;5,14 primary mt-e-
CAFs were isolated from Pdx1-Cre, LSL-K-rasG12D/+, LSL-Trp53R172H /+; LSL-E-
Cadherin-GFP tumors; fl-e-CAFs were isolated from Pdx1-Cre, LSL-K-rasG12D/+,
LSL-Trp53fl/+; LSL-E-Cadherin-GFP tumors. Also see ref. 39 for details on the
generation of the LSL-E-Cadherin-GFP mouse. Isolation of cancer cells was pre-
viously described18. Cancer cells were maintained in Dulbecco’s modified Eagle
media (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin in
20% O2 and 5% CO2. Cells were tested for the presence of mycoplasma (negative
results), and their identity and purity throughout our in vitro experiment were
confirmed via morphological analysis and growth properties. For isolation of CAFs,
mice bearing well-established tumors (>150 days old) were sacrificed; primary
tumors were surgically excised, mechanically dissociated in a tissue culture hood
using a scapel blade and plated into tissue culture flasks in DMEM supplemented
with FBS (10%) and 1% penicillin/streptomycin in 20% O2, 5% CO2. After one
week of culture, cells had attached and grown on the tissue culture dish and
primary CAF cultures were then enriched and purified using a FACS Aria III Cell
Sorter (BD Biosciences, USA). Single-cell suspensions of 1 × 106 cells were incu-
bated with the anti-CD16/CD32 antibody (Mouse BD Fc Block; 1:200, BD Bios-
ciences) in FACS buffer (PBS, 2% FBS, 2% HEPES) to block non-specific antibody
binding. Single-cell suspensions were then pelleted and resuspended in FACS
buffer containing the following cocktail of antibodies: anti-EpCAM-PerCP/Cy5.5
(1:500, BioLegend®, Clone: G8.8), anti-CD140a-APC (1:100; BioLegend®, Clone:
APA5) and anti-Podoplanin-PE (GP38) (1:1,000, BioLegend®, Clone: 8.1.1) for
20 min on ice. Cells were then washed twice in FACS buffer before being resus-
pended in FACS buffer containing DAPI (1:1,000; Invitrogen) to discriminate live
and dead cells. CAFs were isolated according to the following cell surface markers:
CD140a+/GP38+/EpCAM−/DAPI−. Following CAF isolation, CAF were re-plated
on a tissue culture dish and expanded. To prevent alterations of CAFs phenotype
due to tissue culture, we utilized low passages of CAFs in vitro and for in vivo
injection. CAF activation and purity were validated using live imaging of E-
Cadherin-GFP as well as IHC and IF analyses. CAFs that had been isolated based
on gp38 and CD140a positive expression and EpCAM negative expression, and
that were also FAP+, ACTA+, GFP−, keratin 19− and E-Cadherin− were used for
experiments. Telomerase-immortalised fibroblasts (TIFs), used for the generation
of cell-derived matrices (Supplementary Fig. 2d-h), were generated as previously
described22. mt-CCs, fl-CCs, mt-e-CAFs, fl-e-CAFs, and TIFs were cultured in
DMEM (Gibco) complemented with 10% FBS and 1% penicillin/streptomycin in
20% O2, 5% CO2. Cancer cells were engineered to express the mCerulean-YFP
CDK1-FRET biosensor designed by Gavet and Pines71,72 or GFP using a third-
generation lentiviral packaging system followed by selection using blasticidin or via
FACS on an Aria III Cell Sorter (BD Biosciences, USA). CAFs were engineered to
express t-RFP using a retroviral packaging system followed by enrichment by FACS
sorting (FACS Aria III Cell Sorter (BD Biosciences, USA)). Mutant p53R175H and
PCB6+ 1 control (empty vector, EV) vectors were a kind gift from Karen Vousden
(BICR, Glasgow, UK).
Immunoblotting. Cells were lysed in protein extraction buffer (50 mM HEPES, 1%
Triton-X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.5 mM EDTA, 50 mM NaF,
Fig. 6 Paracrine signaling between mt-CCs and CAFs mediated by NFκB induces HSPG2 expression. a Heat map of microarray analysis of NFκB-target
genes in fl-CCs versus mt-CCs (n= 3 independent replicates per cell line). b Heatmap and c quantification of multiplexed analysis of NFκB canonical
signaling in fl-CCs, mt-CCs and their matched CAFs. n= 3 biological repeats. Data are normalized to fl-cells. d Western Blot analysis of pIκBα (S32) and
IκBα at baseline in cancer cells and in their matched CAFs. e ELISA quantification of TNFα in conditioned media generated by fl-CCs and mt-CCs. n= 3
biological repeats. f Heat map and g quantification of multiplexed analysis of NFκB canonical signaling in fl-e-CAFs upon treatment with TNFα and in
untreated mt-e-CAFs. hWestern Blot analyses of pIκBα (S32) and IκBα in fl-e-CAFs upon stimulation with TNFα. i RT-qPCR analysis of HSPG2 expression
in fl-e-CAFs upon treatment with TNFα. j Schematic of paracrine signaling between mt-CCs and the surrounding fibroblasts to drive HSPG2 secretion in the
tumor microenvironment. k Representative images of HSPG2 staining and quantification of optical density in stromal areas of pancreatic tumors isolated
from KPflC mice (n= 6) and KPC mice (n= 9). Individual data points are presented with mean values and SEM. Scale bar: 200 µm. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001
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10 mM Na3VO4, and protease cocktail inhibitor (Roche)). Lysates were separated
by electrophoresis on a 10% acrylamide Bis-Tris gel or on a 4–12% gradient
acrylamide Bis-Tris gel. Proteins were subsequently transferred onto a PVDF
membrane (Immobilon-P, Millipore), blocked with 5% milk or with 1% BSA,
incubated with primary antibodies (IκBα (1:1000), Cell signalling #9246 and pIκBα
(S32, 1:1,000), Cell Signaling #9246) overnight at 4 °C, and probed with HRP-
linked secondary antibodies (GE Healthcare, 1:5,000 diluted in 1% milk or in 1%
BSA). Signal was detected using ECL reagent (Pierce) on a Fusion Fx7 ECL Imager.
Signal was normalized to GAPDH or to actin expression. Raw data of immuno-
blotting can be found in the source data file.
Organotypic assays. Organotypic assays were adapted from previously published
protocols22.
Contraction assay: Rat-tail tendon collagen was extracted with 0.5 mM acetic
acid to a concentration of 2.5 mg per ml. 2 × 105 fl-CAF or mt-CAF were
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Fig. 7 mt-e-CAFs impair cancer cell response to standard-of-care gemcitabine/Abraxane in vitro. a Representative images and quantification of
Ki67 staining and of b cleaved-caspase 3 (CC3) staining of fl-CCs and mt-CCs invading into fl-e-CAF matrices upon treatment with control or with
gemcitabine (100 nM)/Abraxane (100 nM) for 72 h. Scale bar: 50 μm, n= 3 biological repeats with three technical replicates per biological repeat.
c Representative images and quantification of Ki67 staining and of d CC3 staining of fl-CCs and mt-CCs invading into mt-e-CAF matrices upon treatment
with control or with gemcitabine (100 nM)/Abraxane (100 nM) for 72 h. Scale bar: 50 μm, n= 3 biological repeats with three technical replicates per
biological repeat. e Schematic representation of the CDK1-FRET biosensor (adapted from 32) and representative mCerulean lifetime maps showing high
CDK1 activity or low CDK1 activity as assessed via FLIM-FRET imaging of the CDK1-FRET biosensor. f Schematic representation of co-seeding of CAFs and
cancer cells expressing the CDK1 biosensor on dishes coated with native fibrillar collagen, treatment with gemcitabine/Abraxane and FLIM-FRET imaging
of CDK1 activity in cancer cells. g Representative mCerulean lifetime maps and h quantification of mCerulean lifetimes and i. CDK1 activity in fl-CCs
cultured alone, cultured with fl-e-CAFs or with mt-e-CAFs and treated with control or with gemcitabine (100 nM)/Abraxane (100 nM) for 24 h. Scale bar:
100 μm, n= 3 biological repeats. j Representative mCerulean lifetime maps and k quantification of mCerulean lifetimes and l CDK1 activity in mt-CCs
cultured alone, cultured with fl-e-CAFs or with mt-e-CAFs and treated with control or with gemcitabine (100 nM)/Abraxane (100 nM) for 24 h. Scale bar:
100 μm, n= 3 biological repeats, >100 cells analyzed per condition. Individual data points are presented with mean values and SEM. *p < 0.05
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embedded in 2.5 mL of rat-tail collagen I. Once polymerized, fibroblast-collagen
matrices were allowed to contract in DMEM containing 10% FBS and 1%
penicillin/streptomycin for 12 days (or for 24 days in extended contraction assay,
Supplementary Fig. 1a), with a media renewal at day 6. For treatment with
conditioned media, 50% DMEM containing 10% FBS and 1% penicillin/
streptomycin was added with 50% of conditioned media (CM), and this was
renewed at day 6. For pharmacological removal of CAFs after matrix
establishment, matrices were treated with puromycin (5 μg per ml) for 48 h,
followed by 3 × 30min washes in warm PBS.
Invasion assay: After contraction, 4 × 104 cancer cells (fl-CC, mt-CC or a 50:50
mix of fl-CC:mt-CC) were seeded on the contracted matrix in DMEM containing
10% FBS and 1% penicillin/streptomycin and allowed to grow for 4 days. The
matrix was then transferred to a metal grid, raised to an air-liquid interface and
cancer cells were allowed to invade for 12 days. For experiments with CAFs seeded
in the liquid phase during invasion, DMEM only or 1 × 106 fl-e-CAFs or mt-e-
CAFs were seeded in DMEM containing 10% FBS and 1% penicillin/streptomycin
into a 6-cm dish 24 h prior to transferring the metal grid supporting the matrices in
the dish containing the CAFs. DMEM and CAFs were renewed every 72 h during
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the 12-day invasion phase. After invasion, organotypic matrices were imaged or
fixed in 10% formalin and processed for histochemistry analyses. Invasive index
was measured in three representative areas per matrix and as per the formula:
Invasive index ¼ Number of invading cells
Number of invading cellsþ number of non invading cellsð Þ ´ 100
Clusters of cells invading together were defined as more than four cancer cells in
close proximity and invading together into the CAF-collagen matrix.
For assessment of Ki67 and cleaved-caspase 3 (CC3) staining, the ratio was
normalized to the value for mt-CCs treated with control. For each experiment, cells
were counted in three fields of view per matrix, with three matrices per repeats and
three biological replicates in total.
Imaging and quantification of collagen birefringence. Paraffin-embedded
samples were cut into 4 µm sections and stained with 0.1% picrosirius red (Poly-
sciences) for fibrillar collagen according to manufacturer’s instructions. Polarized
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light imaging was performed on a Leica DM 4000 microscope and using an
Olympus U-POT polarizer in combination with an Olympus U-ANT transmitted
light analyzer fitted to the microscope. For assessment of picrosirius red staining in
GEMMs tumors, representative polarized light images and quantification of total
coverage of picrosirius red-stained tumors sections with six regions of interest
(ROI) per tumor were analyzed blinded to the tumor genotype. In each tumor,
areas of necrosis (where present) and tumor boundaries with normal tissue were
excluded from analysis.
Immunohistochemistry staining. Tissues fixed in 10% buffered neutral formalin
and embedded in paraffin were cut as 4 μm sections. Sections were de-paraffinized
using xylene and rehydrated in graded ethanol washes. Antigen retrieval was
achieved via target retrieval solution low-pH (DAKO S1699) for 30 min at 93 °C for
organotypic samples and at 100 °C for mouse or human tissues. Slides were sub-
sequently quenched in 3% H2O2 before application of protein block (Dako) and
incubation with primary antibodies (ACTA 1:200, Abcam #ab5694; Pab421 1:100,
Merck Millipore; cleaved-caspase 3 1:200, Cell Signalling #9661; Ki67 1:500
Thermo fisher; and A7L6 HSPG2 1:300, Merck Millipore). Secondary antibodies
(Envision) coupled to HRP were then applied and detection was performed with
diaminobenzidine (DAB). H&E staining and counterstaining were done on the
Leica autostainer XL. Quantification of DAB intensity was performed in ImageJ.
DAB optical density was measured using color deconvolution and the average DAB
intensity was computed for each cell.
Immunocytochemistry staining. Cells seeded on a glass coverslip were washed
three times in warm PBS prior to fixation in 4% paraformaldehyde (PFA, 10 min,
room temperature). Cells were subsequently permeabilized with 0.5% Triton-X-100
(10 min, room temperature), quenched with 3%H2O2 (30 min, room temperature),
blocked with a protein block (Dako, 30 min, room temperature) and incubated
overnight with primary antibodies (ACTA2 1:200, Abcam #ab5694; cleaved-
caspase 3 1:200, Cell Signalling #9661; Ki67 1:500, Thermo Fisher, A7L6 HSPG2
1:300 (mAb targeting domain IV of mouse HSPG2, Merck Millipore; CCN1 1:1000
(anti-HSPG2 antibody, developed by the Whitelock laboratory) and t-RFP 1:100,
Evrogen #AB233). Subsequently, secondary antibodies (Envision) coupled to HRP
were applied and detection was performed with DAB.
Immunofluorescence staining. Cells were seeded on glass coverslips, washed in
PBS and fixed in 4% PFA (10min, room temperature). Cells were permeabilzed
using Triton-X-100 (10min, room temperature), blocked with 2% BSA (2 h, room
temperature) and incubated with primary antibodies (E-Cadherin 1:200, BD Bios-
ciences #610182; FAP 1:500 Abcam #53066; keratin 19 1:50, DSHB USA) overnight
at 4 °C. Cells were incubated with Alexa488- or AlexaCy5-coupled secondary
antibody (Jackon ImmunoResearch Laboratories Inc., 1:5,000, 1 h at room tem-
perature), counter-stained with DAPI, and mounted in Mowiol mounting medium.
Second Harmonic Generation (SHG) imaging and analysis. Second Harmonic
Generation imaging is a label-free imaging technique that allows imaging of non-
centrosymmetric entities such as collagen fibers. Production of a SHG signal occurs
when two photons with the same wavelength fuse into a single photon with half of
the original wavelength upon interacting with a non-centrosymmetric entity. SHG
signal was acquired using a Leica DMI 6000 SP8 inverted confocal microscope with
a 25 × 0.95 NA water objective. The excitation source was a Ti:Sapphire femtose-
cond laser cavity (Coherent Chameleon Ultra II) operating at 80 MHz and tuned at
a wavelength of 880 nm. Intensity was recorded with a RLD HyD detector (440/
20 nm). Three 512 × 512 representative regions of interest were imaged per sample,
with a line average of 3 and over a 3D z-stack (50 μm depth with a z-step size of
2.5 μm on fresh samples and 20 μm depth with a z-step size of 1.52 μm on cut tissue
sections). SHG signal intensity was measured using Matlab (MathWorks). Repre-
sentative images of maximum intensity projections are shown.
Grey-level co-occurrence matrix. Collagen fiber network organization was
characterized using grey-level co-occurrence matrix (GLCM) analysis. This method
provides a readout of the texture of a sample by quantifying the similarity between
pixels across an image44. The correlation curves represent the similarity in signal
intensity between pixels acquired via single-plane SHG imaging of collagen fibers
(line average for SHG acquisition: 16). A slower decay shows a more organized
network of collagen fibers than in samples with a faster decay. GLCM analysis was
performed in Matlab (Mathworks) as previously described44. The GLCM corre-
lation parameter for each image was calculated using looped operation of the plug-
in and for 0°, 90°, 180°, and 270° directions. Normalized correlations were calcu-
lated in MATLAB (MathWorks) and the mean correlation was plotted against the
neighbor index in GraphPad software.
Shear rheology measurements. Storage modulus in matrices remodeled by CAFs
was measured on a Discovery Series Hybrid DHR-3 controlled stain rotational
rheometer (TA Instruments) using a 8 mm sandblasted parallel plate geometry.
Following calibration of the rheometer according to the manufacturer’s instruc-
tions, the axial force was set to zero and the CAF matrices were subjected to a
controlled strain with a continuous oscillation and with an oscillation frequency of
0.5 rad per sec; an oscillation strain ranging from 0.2% to 2.0% and an axial force of
0.03 N; a conditioning time of 2.0 s and a sampling time of 3.0 s. Ten data points
per decade were acquired. Storage modulus was determined as the mean value
within the linear viscoelastic range.
Atomic force microscopy (AFM) measurement of matrix stiffness. CAF-
collagen matrices were immobilized on a 40 mm glass bottom cell culture dish
using a 10% agarose solution (Bioline Australia). Nano-indentation was performed
on a Bioscope Catalyst (Bruker) mounted on a TMC anti-vibration table (Technical
Manufacturing Corporation) and using a 1 μm spherical colloidal probe (Novas-
can) with a spring constant of 0.06 N per m mounted on the fluid holder of the
AFM scanner. Prior to measurements, AFM calibration was performed by mea-
suring the deflection sensitivity of the probe in fluid by engaging the probe on an
uncoated glass substrate, withdrawal of the probe, and then using a thermal tune
sweep to determine the spring constant. Indentation was performed using a peak
force tapping mode (average loading force of 1 nN) on three different areas per
matrix and ten indentations points per area. The Hertz spherical indentation model
was used to calculate the Young’s modulus values22.
Media conditioning. Cancer cells and CAFs plated in a tissue culture dish and
reaching 75% confluence were washed three times using phosphate-buffered saline
and were subsequently cultured for 24 h in DMEM Phenol Red free (Gibco) media
complemented with 1% penicillin/streptomycin in 20% O2/5% CO2. Conditioned
media were then collected, passed through a 0.2 μm filter and spun at 200 g for
10 min to remove cell debris. Conditioned media were either used fresh or stored at
−80 oC before being used during contraction assays. For immunoblotting and
mass-spectrometry assessments, conditioned media were concentrated using
ultrafiltration columns (3-50 kDa →100 kDa, Sartorius) and normalized to a
concentration of 20 μg per 10 μl.
Real-time quantitative polymerase chain reaction. RNA samples were isolated
at the Garvan Molecular Genetics facility using the Macherey–Nagel Nucleospin
RNA plus kit, according to the manufacturer’s instructions. RNA was reverse
transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche Diag-
nostics) and cDNA was synthesized from 1 μg of total RNA and diluted 1:10.
Subsequent RT-qPCR experiments were performed using the Roche Universal
Probe Library System on a Roche LightCycler480® (Roche LifeScience). Probes and
programs used for RT-qPCR analysis are described in Supplementary Data 3 and 4.
Relative mRNA expression levels were normalized to GAPDH and
quantification was performed using the comparative CT method described
previously43 for each biological replicate.
CDM establishment and monitoring of cell streaming. CDMs were generated as
previously described54. In brief, confluent Telomeraze-immortalized fibroblasts
were exposed to 50 μg per ml ascorbic acid for 7 days prior to denuding cells. For
streaming experiment, cells (25% GFP-cancer cells and 75% RFP-CAFs) were
seeded onto the resulting CDMs and longitudinally imaged using an Incucyte over
72 h. Cell streaming anisotropy was quantified using FibrilTool55 in the GFP
channel to measure directionality-dependent coordinated cell migration, as pre-
viously performed22.
Local invasion in subcutaneous xenograft experiment. 1×106 cells (25% cancer
cells, 75% CAFs) were resuspended as single cells in 50 μl PBS, maintained on ice
before being subcutaneously injected into the rear flank of BALB/c-Fox1nuAusb
mice under anaesthesia (isoflurane 3 L, O2 1 L min per, vacuum was used con-
stantly to remove excess of O2). Tumor volume was measured daily. When average
tumor volume reached 100 mm3, mice were sacrificed and subcutaneous xenografts
were collected and fixed in 10% formalin buffer. Cell invasion into subcutaneous
fat, muscle, and skin was analyzed using the scoring system described in Supple-
mentary Fig. 3. This was scored blinded by two separate researchers, as previously
described25.
Orthotopic injections and monitoring of tumor progression. Cancer cells and
CAFs were resuspended as single cells, counted on an automated cell counter,
serially diluted to obtain a mix of 50 luciferase-cancer cells and 150 CAFs. Cells
were mixed in a volume of 50 μL PBS/Matrigel (1:1 mix), maintained on ice before
being injected into the pancreas of NOD/SCID/ILR2γ mice under anesthesia
(isoflurane 3 L, O2 1 L per min, vacuum was used constantly to remove excess of
O2) during open laparotomy. Tumor growth and metastatic spread were monitored
twice weekly via IVIS imaging. Mice were administered with Luciferin (150 mg per
kg, Gold Biotechnology) via intraperitoneal injection and signal was acquired on an
IVIS Spectrum with open filters and small binning. Time to metastasis was
determined when Luciferase signal was detected in areas outside the pancreatic
zone. Experimental endpoints were defined as development of general signs of
disease/discomfort (dehydratation, prolonged hunching, ruffled coat, fluid built up
in the abdomen, abdominal distension, reduced movement/reactivity, obvious
lesions or huddling in cage corner) or weight loss ≥10% of body weight.
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In this manuscript, we utilized both subcutaneous xenografts and orthotopic
injections of pancreatic cancer cells with CAFs. The subcutaneous model is a rapid
model, which we and others previously optimized and employed for rapid
assessment of early tumor growth, local invasion and response to treatments22,25.
The orthotopic model was optimized to monitor distinct steps of tumor
progression, onset of metastasis and response to treatment in a native tissue.
In the subcutaneous xenograft experiment presented in Fig. 9, experimental
endpoint was determined as maximum tumor volume of 350 mm3 (measured with
calipers). In the orthotopic model, determination of tumor burden and
experimental endpoint in Fig. 4 was achieved via IVIS imaging. However, in Fig. 9,
the additional burden of administration of gemcitabine/Abraxane precluded IVIS
imaging and experimental endpoints were determined using clinical signs of illness
(including but not limited to change in animal behavior, prolonged hunching,
development of ascites, apathy, overnight weight loss >10%).
Determination of the number of mice required to detect statistical significance
was performed in line with 3Rs requirements. For changes in local invasion, we
estimated an incidence of local invasion in ~75% of mice injected with mt-CCs
(based on previously published work22,25,39). Changes in the incidence of
metastasis to ~25% was expected, and the predicted standard deviation was 20%.
Using these figures, and type-1 error α= 0.05, we could identify a difference in
local invasion to a power of β= 80% at a significance level of 5% in cohorts of four
mice per group. Statistical assessments were performed using unpaired multi-group
comparisons by the Kruskal–Wallis test. However, to account for censored events,
where tumor growth may not occur, an additional mouse was included per group.
Microarray transcript expression profiling. Total RNA was isolated using the
RNeasy extraction kit (Qiagen) and measured on the 2100 Bioanalyzer (Agilent).
Total RNA was converted to cDNA, biotin labeled and then hybridized to the
Affymetrix mouse GeneChip 430 2.0 Arrays, as per the manufacturer’s instructions
(Affymetrix Ca, USA), at the Paterson/Beatson Institute (UK). All cells were pre-
pared in biological triplicate for each experimental group. Quality control was
performed using the affy R package81. Normalization and probe-set summarization
was performed using the robust multichip average (RMA) method82. Differential
expression between experimental groups was performed using Partek® Genomics
Suite® software, Copyright©; Partek Inc., St. Louis, MO, USA. All transcript probe-
sets with an adjusted step-up p-value ≤ 0.05 were classed as differentially regulated
between the samples. Where applicable, genes annotated to multiple probe-sets
were collapsed to a single representative probe-set by selecting the one with the
most significant adjusted p-value. Microarray data are freely available from GEO
GSE123646.
A core set of genes (Bcl2, Cxcl1, Cxcl12, Nfkbia, Tnfrsf9, Tmfsf11) from the
NFKB pathway were identified as significantly differentially regulated (adjusted
p-value ≤ 0.05) between the Trp53 and Trp53 (R172H) cells. We then extended this
to look at other members of the pathway, identifying a further 35 genes that
showed significantly higher expression in the mt-CCs (mutant cancer cells Trp53
R172H) cells compared to the fl-CCs (Trp 53 knockout controls).
GSEA analysis. Functionally associated gene-sets were identified using pre-ranked
Gene Set Enrichment Analysis (GSEA) against the Hallmark (v6.2) gene-sets. For
this the ranked gene list was derived from limma moderated t-statistics comparing
the mt-CCs to the fl-CCs. Genes annotated to multiple probe-sets were collapsed to
a single representative “best” probe-set by selecting the one with the largest
absolute t-statistic. Mouse gene-symbols were mapped to their human orthologs
using the ensembl database (version 94). Mouse genes with no annotated human
ortholog were removed and mouse genes mapping to the same human gene
ortholog were again collapsed using the “best” t-statistic approach.
QuPath-based quantification of DAB staining in GEMMs. Pancreatic tumors
from KPC and KPflC mice were stained for HSPG2 (CCN1 1:1000) and scanned
using an Aperio slide scanner. In QuPath, all cells were detected and a classifier was
built via manual detection of >100,000 cancer cells and stromal cells. The classifier
was constructed using all detection parameters but excluding criteria based on
DAB intensity. Next, the classifier was applied and we manually verified that
detection of cancer cells and stromal area was accurate. QuPath was then employed
to measure optical density in stromal areas.
Proteomics analysis of CAF-derived conditioned media. Secreted proteins
contained in conditioned media were lysed using denaturing lysis buffer containing
6M urea, 2 M thiourea, and 100 mM HEPES (pH8). Protein concentration was
measured using QuBit and samples were normalized to 1 μg per μl prior to
reduction using 10 mM TCEP and alkylation with 40 mM chloroacetamide at room
temperature for 30 min. Proteins were then pre-digested with LysC using 1:50
(enzyme:protein ratio), diluted 1:5 with 100 mM HEPES followed by an overnight
digestion with trypsin using a 1:50 (enzyme:protein ratio) at 37 °C. The digests
were acidified to a final concentration of 1% trifluoroacetic acid (TFA) and desalted
using SDB-RPS stage tips. Columns were conditioned with 100% acetonitrile fol-
lowed by 30% methanol containing 0.2% TFA and then re-equilibrated with 0.2%
TFA. Samples were subsequently loaded on columns and washed with 0.2% TFA
followed by 90% isopropanol containing 1% TFA and then eluted with 80%
acetonitrile containing 5% ammonium hydroxide and dried by vacuum
centrifugation.
Peptides were resuspended in 2% acetonitrile, 0.1% TFA and loaded onto a
50 cm × 75 µm inner diameter column packed in-house with 1.9 µm C18AQ
particles (Dr Maisch GmbH HPLC) using an Easy nLC-1000 UHPLC operated in
single-column mode. Peptides were separated using a linear gradient of 5–30%
Buffer B over 150 min at 300 nL per min (Buffer A= 0.1% formic acid; Buffer B=
80% acetonitrile, 0.1% formic acid). The column was maintained at 60 °C using a
PRSO-V1 ion-source (Sonation) coupled directly to a Q-Exactive mass
spectrometer (MS). A full-scan MS1 was measured at 35,000 resolution at 200 m
per z (300–1650 m per z; 100 ms injection time; 3e6 AGC target) followed by
isolation of up to 15 most abundant precursor ions for MS/MS (2 m per z isolation;
27 normalized collision energy; 17,500 resolution at 200 m per z; 60 ms injection
time; 1e5 AGC target). Raw data were processed using MaxQuant version 1.5.8.3
[PMID: 19029910] using all default parameters with MaxLFQ and match between
runs enabled. Data were searched against the mouse UniProt database and filtered
to a 1% false discovery rate (FDR) at the peptide spectral match and protein level.
Data were further processed with Perseus version 1.5.3.0 [PMID: 27348712] using
t-tests and ANOVA and adjusted for multiple hypotheses testing using
permutation-based FDR to obtain q-values.
The volcano plot (Fig. 4a) represents the Student t-test statistic and the fold
change between each condition for secreted proteins identified by proteomics
analyses. The heat-map (Supplementary Fig. 5a) plots the absolute (log2)
expression levels of each of the secreted proteins that are significantly differently
expressed between fl-e-CAFs and mt-e-CAFs (also see Supplementary Data 1).
Generation of KO and KRAB lines with CRISPR-Cas9. Mammalian codon
optimized S.Py. Cas9 with C-terminal nucleoplasmin NLS tag (kind gift from
Doudna lab) was cloned into a third-generation lentiviral vector downstream of an
EFS promoter and fused to puromycin resistance protein with a P2A peptide.
Single-guide RNA (HSPG2 DNA target sequence (PAM): 5’-GCAGGTCCTCAT
CATCAGAG(AGG)-3’ located on exon 2 of mouse HSPG2) was also cloned into
the same vector downstream of a U6 promoter. The Cas9 lentiviral vector was
transfected into HEK293T cells together with psPAX and pMD2.G packaging and
envelope vectors (gifts from Trono lab, Addgene #12260 and #12259 respectively)
with PEI (Sigma). Lentiviral particles were harvested from culture media, filtered
through 0.45 µm filter units and used to infect CAFs. After 48 h, CAFs were
selected for puromycin resistance (40 µg per ml) and sorted by flow cytometry to
obtain monoclonal populations. Editing was verified by Sanger sequencing at the
genomic locus as follows: cells were lysed in QE buffer (Epicenter) at 65 °C for
20 min followed by 95 °C for 20 min; the locus amplified by PCR using Kapa
HotStart polymerase (Fwd primer: 5’-CCTGCTCATGTCTTTCCAGGT-3’ and
Rev primer: 5’-GCCTGGAACTCCTGATCCTT-3’) and sequenced. T7E1 assay
was performed using the same primers provided in Supplementary Data 3.
For CRISPR-Cas9 interference (CRISPRi), S.Py. Cas9 was rendered catalytically
inactive by introducing D10A and H840A mutations and cloned in frame with a
KRAB domain at its N-terminus into the third-generation lentiviral vector. Single-
guide RNA was designed to bind the following genomic DNA sequence (PAM): 5’-
GAGCACGTGGTGTGAAGGAG(CGG)-3’ in the CpG islands upstream of
HSPG2 gene. Lentiviral particles were generated as described previously in
HEK293T cells and used to infect CAFs. After puromycin selection, HSPG2
expression levels were assessed by RT-qPCR using probes targeting exons 4, 6–7,
22 and 74 to confirm repressed HSPG2 expression.
In vitro doubling time quantification. CAFs were pre-treated with mitomycin-c
(10 μg per ml, 24 h) and were seeded with cancer cells (75% CAFs, 25% cancer
cells). After 48 h of co-culture, cells were harvested and counted on a hemato-
cytometer. Doubling time was calculated as per the formula: DT ¼ T ´ ln2
ln XeXbð Þ, (with
DT: doubling time, T: time of co-culture (48 h), Xe: cancer cell number at endpoint,
Xb: cancer cell number at T= 0).
ELISA. Quantification of TNFα in conditioned media was performed using ELISA
kits (TNFα: Abcam #ab100747) as per the manufacturer’s instructions.
Magpix analysis of canonical NFkB signalling. Multiplexed analysis on the
Magpix platform was performed using a MILLIPLEXMAP NFkB Signaling Mag-
netic Bead Kit (#48-630MAG) and according to the manufacturer’s instructions.
Implantation of titanium window for longitudinal imaging. Twenty-four hour
prior to the surgery and for 72 h following implantation of the window, mice were
kept on Carprofen (5 mg per kg, Rimadyl). Pain management was achieved via
injection of buprenorphine (0.2 mg per kg, Temgesic) prior to surgery as well as 6 h
post-surgery. Mice were anesthetized (isoflurane 3 L, O2 1 L per min, vacuum was
used constantly to remove excess of O2), the incision site was disinfected with 70%
ethanol and an incision was made in the skin above the palpable subcutaneous
xenograft. A purse string suture (Mersilk) was placed through the skin alone to
create a continuous suture around the incision site. A titanium window ring with a
12-mm glass coverslip was then inserted into the incision site and the suture was
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tightened. Four days following surgery, mice were treated with saline or with
gemcitabine/Abraxane and mice were imaged on day 5, 6 and 7 post-surgery.
Drug treatment. Abraxane (Specialized Therapeutics) was administered to mice
by intraperitoneal injection at 30 mg per kg and was used at 100 nM for in vitro
experiments. Gemcitabine (Jomar Life Research) was administered to mice by
intraperitoneal injection at 70 mg per kg and was employed at 100 nM for in vitro
experiments. Recombinant mouse TNFα protein (Abcam #ab9740) was used
in vitro at 10 ng per μl.
FLIM-FRET imaging and analysis. FLIM-FRET imaging was performed using the
system described above (SHG imaging). mCerulean was excited at 840 nm, and the
signal was detected using a 483/32 nm filter. FLIM data were recorded using a
Picoharp 300 TCSPC system (Picoquant). Images of 512 × 512 pixels were acquired
with a line rate of 600 Hz. The pixel dwell time was 5 μs, and images were inte-
grated until 500 photons per pixel were acquired. For in vivo measurements of
mCerulean lifetimes in live xenografts, cancer cells expressing the CDK1-FRET
biosensor were trypsinized and resuspended in cold phosphate-buffered saline
(PBS) with CAFs. 1 × 106 cells were injected subcutaneously into the rear flank of
BALB/c-Fox1nuAusb mice under anesthesia (isoflurane 3 L, O2 1 L per min,
vacuum was used constantly to remove excess of O2). During imaging, the mouse
was maintained under anesthesia (isoflurane 3 L, O2 1 L per min) and placed on a
37 °C stage. mCerulean lifetimes were analysed as previously described22, by
drawing regions of interest around subcellular areas and recording the lifetime (τ)
of the single exponential function fit to the fluorescence decay data. Lifetime maps
were generated with intensity thresholds set to the average background pixel value
for each recording. The raw data were smoothened, and a standard rainbow color
look up table (LUT) was applied, with lifetimes of 1.9–2.8 ns for mCerulean. Areas
where no lifetime measurement above the background noise could be achieved are
shown in black in the lifetime map.
In the control (untreated situation), the mCerulean lifetime is high while upon
treatment with gemcitabine/Abraxane, the mCerulean lifetime decreases. Stratified
readouts from the mCerulean lifetimes were used as a threshold for cells being
classified as CDK1 high versus CDK1 low. The threshold lifetime was set as the
midpoint between the population means of the untreated and treated groups. The
same threshold was employed to classify cells in the in vitro experiments. For the
longitudinal intravital imaging experiments, the threshold was calculated based on
values between untreated and treated mice at 24 h post-treatment with
gemcitabine/Abraxane for each group of cells co-injected subcutaneously. Single-
cell FLIM-FRET imaging of 60 cells per tumor in 5 different areas of the tumor and
in three mice per treatment group were imaged.
Assessment of mouse survival in the subcutaneous tumor model. 1 × 106 cells
(25% cancer cells, 75% CAFs) in 50 μl PBS were subcutaneously injected into the
rear flank of BALB/c-Fox1nuAusb mice under anaesthesia (isoflurane 3 L, O2 1 L
per min, vacuum was used constantly to remove excess of O2). Once mice devel-
oped palpable tumors, mice treatment with saline control or with gemcitabine/
Abraxane was initiated. Mice were treated twice weekly, on day 1 and day 4. Tumor
volume was measured daily. Experimental endpoint was reached when tumor
volume reached 350 mm3.
Assessment of mouse survival in the orthotopic model. Fifty cancer cells
expressing luciferase and 150 CAFs in 50 μl PBS:Matrigel (1:1) mix were injected
into the pancreas of NOD/SCID/ILR2γ mice under anesthesia (isoflurane 3 L, O2
1 L per min, vacuum was used constantly to remove excess of O2) during open
laparotomy. Once tumor establishment was confirmed via IVIS whole-body ima-
ging, mice entered cycles of treatment with gemcitabine and Abraxane twice
weekly. Mice were monitored daily, and when mice showed signs of clinical illness
(dehydratation, prolonged hunching, ruffled coat, fluid built up in the abdomen,
abdominal distension, reduced movement/reactivity, obvious lesions, or huddling
in cage corner) or weight loss ≥10% of body weight, they were sacrificed and tissues
were collected for further analysis.
Reporting summary. A reporting summary for this article is available as a Sup-
plementary Information file.
Data availability
The microarray data have been deposited in the GEO database under the accession code
GSE123646. The source data underlying Fig. 1-9 are provided as a Source Data file. All
the other data supporting the findings of this study are available within the article and its
supplementary information files and from the corresponding author upon reasonable
request.
Code availability
GLCM analysis was performed using previously published code8, the code for FLIM
analysis was developed by Dr. Aleš Benda and as previously published8.
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